Sotera Health beats top-line and bottom-line estimates; reaffirms FY26 outlook

Sotera Health reported Q3 2026 earnings, with Non-GAAP EPS of $0.29, beating estimates by $0.02. Revenue was $324.89M, up 4.4% year-over-year and $5.01M above expectations. Adjusted EBITDA rose 3.9%. The company reaffirmed its full-year 2026 net revenue outlook.

Original reporting
Published Nov 3, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SHC
Bullish
high confidence
Mentioned
$SHC
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SHCBullishHigh
01

Why it matters

The earnings beat and reaffirmed FY26 outlook provide a fresh catalyst that can drive short‑term price appreciation.

02

Market read

The surprise earnings beat offers a clear trading signal for SHC and may influence related health‑tech stocks.

03

What to watch

Potential headwinds from reimbursement policy changes or competitive pressures not discussed in the release.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Sotera Health (SHC) is a provider of revenue cycle management and health‑technology services. The Q3 2026 results were released via a press release.

Company-level read

Ticker impact

$SHCBullishHigh confidence
Context

Sotera Health reported Q3 2026 Non‑GAAP EPS of $0.29 beating estimates and revenue of $324.89M (+4.4% YoY), reaffirming FY26 outlook.

Expected impact

likely upward pressure as the market prices in the earnings beat and reaffirmed outlook

Evidence & confidence

Both top‑line and bottom‑line exceeded expectations, a fresh primary disclosure that typically drives short‑term buying.

Market effects

Positive earnings may lift the healthcare services sector and peers focused on revenue cycle management.

Limited to U.S. markets where SHC trades.

Modest; primarily affects investors tracking U.S. health‑tech stocks.

Counterpoint

If guidance remains modest, the beat may be priced in quickly, limiting upside.

Key entities

  • Sotera Health

    U.S.-listed health‑tech firm reporting Q3 earnings.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.